ヘモグロビン異常症の世界市場：洞察、競合情勢、市場予測：2030年

世界のヘモグロビン異常症の市場規模は、2024年から2030年までの予測期間中に8.19％のCAGRで拡大し、2030年には1,221万米ドルに達すると予測されています。ヘモグロビン異常症市場は、主に鎌状赤血球貧血、ヘモグロビンC病、ヘモグロビンS-C病、サラセミアなどの様々なヘモグロビン異常症の世界の有病率の上昇により、大幅な市場成長を観察しています。さらに、パイプラインに多数のヘモグロビン異常症が存在すること、鎌状赤血球貧血、サラセミアなどの希少疾患に対する政府や医療機関の関心が高まっていることが、今後数年間のヘモグロビン異常症の需要急増に寄与します。同様に、薬剤の承認・上市の急増に伴う研究開発活動の増加や、市場における主要参入企業の存在は、市場におけるヘモグロビン異常症の必要性を生み出すとみられています。

世界保健機関（WHO）の2022年の推計によると、世界中で毎年30万人以上の重症のヘモグロビン異常症の赤ちゃんが誕生しており、その大部分は中低所得国です。また、世界人口の約5％が鎌状赤血球症（SCD）またはサラセミア遺伝子の健常保因者です。遺伝子の保因者である人の割合は、地域によっては25％にもなります。さらに、これらの疾患は熱帯地域で最も多く見られますが、人口の移動により、これらの疾患はほとんどの国に広がっています。同じ情報源によれば、サラセミアはアジア、地中海沿岸地域、中東で最も一般的な疾患のひとつであり、鎌状赤血球症はアフリカで優勢です。

さらに、疾病管理予防センター（CDC）の最新データでは、鎌状赤血球貧血は毎年約10万人のアメリカ人が罹患しています。また、鎌状赤血球貧血は、黒人またはアフリカ系アメリカ人の出産365件に1件の割合で発生し、ヒスパニック系アメリカ人の出産16,300件に1件の割合で発生しています。

当レポートでは、世界のヘモグロビン異常症市場について調査し、市場の概要とともに、適応症別、治療別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 ヘモグロビン異常症市場レポートのイントロダクション

第2章 ヘモグロビン異常症市場のエグゼクティブサマリー

第3章 規制分析

第4章 ヘモグロビン異常症市場の主な要因分析

• ヘモグロビン異常症市場の促進要因
• ヘモグロビン異常症市場の抑制要因と課題
• ヘモグロビン異常症市場の機会

第5章 ヘモグロビン異常症市場におけるポーターのファイブフォース分析

第6章 ヘモグロビン異常症市場に対するCOVID-19の影響分析

第7章 ヘモグロビン異常症市場の概要

• 適応症別
• 治療別
• 地域別

第8章 ヘモグロビン異常症市場の企業と製品プロファイル

• Global Blood Therapeutics, Inc.
• Sanofi
• bluebird bio, Inc.
• Bristol-Myers Squibb Company
• Emmaus Medical, Inc,
• Novartis
• Merck KGaA,
• Chiesi USA, Inc.
• ApoPharma Inc.
• Alvogen

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Hemoglobinopathies Market
• Table 3: Hemoglobinopathies Market Analysis in Global (2021-2030)
• Table 4: Hemoglobinopathies Market Analysis in Global by Indication (2021-2030)
• Table 5: Hemoglobinopathies Market Analysis in Global by Treatment (2021-2030)
• Table 6: Hemoglobinopathies Market Analysis in Global by Geography (2021-2030)
• Table 7: Hemoglobinopathies Market Analysis in North America (2021-2030)
• Table 8: Hemoglobinopathies Market Analysis in North America by Country (2021-2030)
• Table 9: Hemoglobinopathies Market Analysis in the US (2021-2030)
• Table 10: Hemoglobinopathies Market Analysis in Canada (2021-2030)
• Table 11: Hemoglobinopathies Market Analysis in Mexico (2021-2030)
• Table 12: Hemoglobinopathies Market Analysis in Europe (2021-2030)
• Table 13: Hemoglobinopathies Market Analysis in Europe by Country (2021-2030)
• Table 14: Hemoglobinopathies Market Analysis in France (2021-2030)
• Table 15: Hemoglobinopathies Market Analysis in Germany (2021-2030)
• Table 16: Hemoglobinopathies Market Analysis in the UK (2021-2030)
• Table 17: Hemoglobinopathies Market Analysis in Italy (2021-2030)
• Table 18: Hemoglobinopathies Market Analysis in Spain (2021-2030)
• Table 19: Hemoglobinopathies Market Analysis in the Rest of Europe (2021-2030)
• Table 20: Hemoglobinopathies Market Analysis in Asia-Pacific (2021-2030)
• Table 21: Hemoglobinopathies Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 22: Hemoglobinopathies Market Analysis in China (2021-2030)
• Table 23: Hemoglobinopathies Market Analysis in Japan (2021-2030)
• Table 24: Hemoglobinopathies Market Analysis in India (2021-2030)
• Table 25: Hemoglobinopathies Market Analysis in Australia (2021-2030)
• Table 26: Hemoglobinopathies Market Analysis in South Korea (2021-2030)
• Table 27: Hemoglobinopathies Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 28: Hemoglobinopathies Market Analysis in the Rest of the World (2021-2030)
• Table 29: Hemoglobinopathies Market Analysis in the Rest of the World by Region (2021-2030)
• Table 30: Hemoglobinopathies Market Analysis in the Middle East (2021-2030)
• Table 31: Hemoglobinopathies Market Analysis in Africa (2021-2030)
• Table 32: Hemoglobinopathies Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Hemoglobinopathies Market
• Figure 3: Hemoglobinopathies Market Analysis in Global (2021-2030)
• Figure 4: Hemoglobinopathies Market Analysis in Global by Indication (2021-2030)
• Figure 5: Hemoglobinopathies Market Analysis in Global by Treatment (2021-2030)
• Figure 6: Hemoglobinopathies Market Analysis in Global by Geography (2021-2030)
• Figure 7: Hemoglobinopathies Market Analysis in North America (2021-2030)
• Figure 8: Hemoglobinopathies Market Analysis in North America by Country (2021-2030)
• Figure 9: Hemoglobinopathies Market Analysis in the US (2021-2030)
• Figure 10: Hemoglobinopathies Market Analysis in Canada (2021-2030)
• Figure 11: Hemoglobinopathies Market Analysis in Mexico (2021-2030)
• Figure 12: Hemoglobinopathies Market Analysis in Europe (2021-2030)
• Figure 13: Hemoglobinopathies Market Analysis in Europe by Country (2021-2030)
• Figure 14: Hemoglobinopathies Market Analysis in France (2021-2030)
• Figure 15: Hemoglobinopathies Market Analysis in Germany (2021-2030)
• Figure 16: Hemoglobinopathies Market Analysis in the UK (2021-2030)
• Figure 17: Hemoglobinopathies Market Analysis in Italy (2021-2030)
• Figure 18: Hemoglobinopathies Market Analysis in Spain (2021-2030)
• Figure 19: Hemoglobinopathies Market Analysis in the Rest of Europe (2021-2030)
• Figure 20: Hemoglobinopathies Market Analysis in Asia-Pacific (2021-2030)
• Figure 21: Hemoglobinopathies Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 22: Hemoglobinopathies Market Analysis in China (2021-2030)
• Figure 23: Hemoglobinopathies Market Analysis in Japan (2021-2030)
• Figure 24: Hemoglobinopathies Market Analysis in India (2021-2030)
• Figure 25: Hemoglobinopathies Market Analysis in Australia (2021-2030)
• Figure 26: Hemoglobinopathies Market Analysis in South Korea (2021-2030)
• Figure 27: Hemoglobinopathies Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 28: Hemoglobinopathies Market Analysis in the Rest of the World (2021-2030)
• Figure 29: Hemoglobinopathies Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 30: Hemoglobinopathies Market Analysis in the Middle East (2021-2030)
• Figure 31: Hemoglobinopathies Market Analysis in Africa (2021-2030)
• Figure 32: Hemoglobinopathies Market Analysis in South America (2021-2030)
• Figure 33: Market Drivers
• Figure 34: Market Barriers
• Figure 35: Market Opportunities
• Figure 36: PORTER's Five Force Analysis

Hemoglobinopathies Market By Indication (Thalassemia, Sickle Cell Anaemia, And Others), By Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of various hemoglobin disorders and the increasing research & developmental activities concerning to the hemoglobinopathies across the globe

The global hemoglobinopathies market will grow at a CAGR of 8.19% during the forecast period from 2024 to 2030 to reach USD 12.21 million by 2030. The hemoglobinopathies market is observing substantial market growth primarily due to the growing prevalence of various hemoglobin disorders such as sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, thalassemia, and others across the globe. Further, the presence of a robust number of Hemoglobinopathies in the pipeline, and the increasing focus of governments and healthcare organizations on rare diseases such as sickle cell anemia, thalassemia, and others will aid in surging the demand for Hemoglobinopathies in the upcoming years. Likewise, the increasing research & developmental activities along with the surging drug approvals and launches and the presence of key players in the market will create a requisite for hemoglobinopathies in the market. Therefore, the market for hemoglobinopathies is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Hemoglobinopathies Market Dynamics:

According to the World Health Organization (WHO) 2022 estimates each year over 300,000 babies with severe forms of diseases are born worldwide, the majority in low and middle-income countries. Also, approximately 5% of the world's population are healthy carriers of a gene for sickle-cell disease (SCD) or thalassemia. The percentage of people who are carriers of the gene is as high as 25% in some regions. Further, these conditions are most prevalent in tropical regions; however, population migration has spread these diseases to most countries. As per the same source, Thalassaemia is one of the most common diseases in Asia, the Mediterranean basin, and the Middle East and Sickle-cell disease predominates in Africa.

Furthermore, the Centers for Disease Control and Prevention (CDC) in the latest data stated that sickle cell anemia affects approximately 100,000 Americans, every year. Also, SCD occurs among about 1 out of every 365 Black or African-American births and SCD occurs among about 1 out of every 16,300 Hispanic-American births.

Moreover, the clinical trials of hemoglobinopathies are expected to significantly advance the drug development process. For instance, in August 2022, Vertex Pharmaceuticals Incorporated started a Phase IIIb study to evaluate the efficacy and safety of a single dose of autologous CRISPR Cas9 modified CD34+ human hematopoietic stem and progenitor cells (CTX001) in subjects with transfusion-dependent B-thalassemia or severe sickle cell disease. The trial is anticipated to get completed by February 2025. Therefore, such trials will increase the chance of accessibility of hemoglobinopathies drugs during the forecast period which may create a rewarding chance for the key players to cater to the maximum market and make enormous revenue. Henceforth, the market of hemoglobinopathies will grow during the forecast period from 2022 - 2028.

Lastly, the rising investment in the development of novel therapies is further expected to provide impetus to market growth in the upcoming years. Also, major biopharmaceutical players are collaborating to develop novel therapeutics for hemoglobinopathies using the latest technology platforms. For instance, Sangamo Therapeutics, Inc. and Bioverativ have collaborated to develop therapeutics for hemoglobinopathies.

Therefore, the factors stated above collectively will drive the overall hemoglobinopathies market throughout the forecast period from 2024-2030.

However, the high cost of drug development and launches, low awareness regarding hemoglobinopathies, and stringent regulatory approval process may halt the market growth of hemoglobinopathies.

The hemoglobinopathies market was moderately impacted during the period of the COVID-19 pandemic. During the initial stage of the pandemic, the sale of hemoglobinopathies suffered collapse owing to the imposition of strict lockdown rules, disruption in manufacturing, and supply. However, the government classified medicines and drugs under emergency products during the pandemic, thereby leading to an increase in their demand or sales. However, the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of a vaccine to the public, and with the increasing number of treatment rates for hemoglobin disorders, the demand for hemoglobinopathies increases and is anticipated to do the same during the forecast period from 2022 - 2028.

Hemoglobinopathies Market Segment Analysis:

Hemoglobinopathies Market by Indication (Thalassemia, Sickle Cell Anaemia, and Others), Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the treatment segment of the hemoglobinopathies market, the stem cell therapy segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the efficiency offered by stem cell therapy in the treatment of hemoglobinopathies. Moreover, stem cell therapy also offers lesser side effects as compared to other treatments. Also, the expanding launches and strategic investments, and other activities by the key players will drive the market growth during the forecast period.

For instance, stem cell therapy is generally only considered in children with sickle cell disease who have severe symptoms that have not responded to other treatments, when the long-term benefits of a transplant are thought to outweigh the possible risks.

Also, stem cell therapy reduces disease burden, improves outcomes and quality of life for patients with SCD, and significantly reduces health care costs over the long term.

Moreover, the presence of a robust number of stem cell therapy treating hemoglobinopathies in the pipeline will in turn increase the market opportunity. For instance, in February 2020, bluebird bio started a Phase III study evaluating gene therapy by transplantation of autologous CD34+ stem cells transduced ex vivo with the BB305 lentiviral vector in subjects with sickle cell disease. The study is aimed to evaluate hematopoietic stem cell (HSC) transplantation (HSCT) using bb1111 (also known as LentiGlobin BB305 Drug Product for SCD).

Therefore, owing to the above-mentioned factors, the demand for stem cell therapy upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global hemoglobinopathies market during the forecast period.

Europe is expected to dominate the overall Hemoglobinopathies Market:

Among all the regions, Europe is expected to dominate global hemoglobinopathies in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for hemoglobinopathies in the region owing to the increasing prevalence of various hemoglobin disorders in the region. Further, the presence of key domicile players in the region, surging drug approvals and launches, and others are among the key factors that contribute to the growth of the hemoglobinopathies market in Europe during the forecast period from 2022 - 2028.

According to the 2020 report, Overview of the sickle cell disease environment in select European countries, Sickle cell disease (SCD) is a rare, inherited disorder, affecting more than 52,000 people in Europe, in 2020. It is the most prevalent genetic disease in France, and in the United Kingdom (UK), and its prevalence is increasing in many other European countries. Further, according to figures from the European Medicines Agency (EMA), in 2019 approximately 1 in 10,000 people lived with SCD in the EU/ European Economic Area (EEA).

Furthermore, the increasing activities by the key players and government in the region will in turn increase the demand for the product during the forecast period. For instance, in 2019, the European Joint Programme on Rare Diseases (EJP RD) was launched, to create an ecosystem for research, care, and innovation for rare diseases including hemoglobinopathies. The project has a total of Euro 100 million investment, Euro 55 million of which are contributed by the EU. It includes projects on translational research for rare diseases (translating pre-clinical research to clinical) among others.

Moreover, the market players in the country are continuously concentrating on the development of novel drugs to tackle mental disorders indications using hemoglobinopathies, and they are also adopting various strategies to develop better drugs with reduced side effects. Thus, this is likely to drive the market in the region. For instance, in October 2022, Global Blood Therapeutics started a randomized, double-blind, placebo-controlled, multicenter Phase III study to assess the safety and efficacy of Inclacumab in participants with sickle cell disease experiencing vaso-occlusive crises. The trial is being conducted in Germany, France, Italy, and various other European and North American Locations.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the Europe region in the hemoglobinopathies market.

Hemoglobinopathies Market Key Players:

Some of the key market players operating in the hemoglobinopathies market are Global Blood Therapeutics, Inc., Sanofi, bluebird bio, Inc., Bristol-Myers Squibb Company, Emmaus Medical, Inc, Novartis, Merck KGaA, Chiesi USA, Inc., ApoPharma Inc., Alvogen., and others.

Recent Developmental Activities in the Hemoglobinopathies Market:

In August 2022, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

In November 2019, the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept-aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta-thalassemia who require regular red blood cell (RBC) transfusions.

In November 2019, the U.S. Food and Drug Administration (FDA) approved ADAKVEO (crizanlizumab-tmca) to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

In November 2019, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

Key Takeaways from the Hemoglobinopathies Market Report Study

Market size analysis for current hemoglobinopathies market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the hemoglobinopathies market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global hemoglobinopathies market.

Various opportunities available for the other competitor in the hemoglobinopathies market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current hemoglobinopathies market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for hemoglobinopathies market growth in the coming future?

Target Audience who can be benefited from this Hemoglobinopathies Market Report Study

Hemoglobinopathies providers

Research organizations and consulting companies

Hemoglobinopathies -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in hemoglobinopathies

Various end users who want to know more about the hemoglobinopathies market and the latest developments in the hemoglobinopathies market.

Frequently Asked Questions for the Hemoglobinopathies Market:

1. What are hemoglobinopathies?

Hemoglobinopathies are a group of disorders passed down through families (inherited) in which there is abnormal production or structure of the hemoglobin molecule.

2. What is the global market for hemoglobinopathies?

The global hemoglobinopathies market will grow at a CAGR of 8.19% during the forecast period from 2024 to 2030 to reach USD 12.21 million by 2030.

3. What are the drivers for the global Hemoglobinopathies market?

The hemoglobinopathies market is witnessing positive market growth owing to the factors such as the growing prevalence of hemoglobinopathies, the presence of a robust number of pipeline products across the globe, increasing focus of governments and health care organizations on rare diseases such as sickle cell anemia, thalassemia, and others, surging new drug launches and approvals, presence of key players in the market, and others will create an exigency for the Hemoglobinopathies market.

4. Who are the key players operating in the global hemoglobinopathies market?

Some of the key market players operating in the hemoglobinopathies market include Global Blood Therapeutics, Inc., Sanofi, bluebird bio, Inc., Bristol-Myers Squibb Company, Emmaus Medical, Inc, Novartis, Merck KGaA, Chiesi USA, Inc., ApoPharma Inc., Alvogen., and others.

5. Which region has the highest share of the hemoglobinopathies market?

Among all the regions, Europe is estimated to hold a significant revenue share in the global Hemoglobinopathies market. This can be ascribed to the increasing demand for hemoglobinopathies among the patients in the region owing to the increasing prevalence of various hemoglobin disorders such as sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, thalassemia, and others. Further, the presence of key domicile players and rising new drug approvals in the region are the reasons which act as a supportive factor for the Europe hemoglobinopathies market growth.

Table of Contents

1.Hemoglobinopathies Market Report Introduction

2. Hemoglobinopathies Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Hemoglobinopathies Market Key Factors Analysis

• 4.1. Hemoglobinopathies Market Drivers
  • 4.1.1. Growing prevalence of hemoglobinopathies
  • 4.1.2. Presence of a robust number of pipeline product
  • 4.1.3. Increasing focus of governments and health care organizations on rare diseases such as sickle cell anemia, thalassemia, and others
• 4.2. Hemoglobinopathies Market Restraints and Challenges
  • 4.2.1. High cost of drug development and launches
  • 4.2.2. Low awareness regarding hemoglobinopathies
• 4.3. Hemoglobinopathies Market Opportunities
  • 4.3.1. Rising investment by the government and key players for the development of novel therapies and to create awareness regarding the treatments available
  • 4.3.2. Increasing awareness regarding the treatment for hemoglobin disorders in the emerging countries

5. Hemoglobinopathies Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Hemoglobinopathies Market

7. Hemoglobinopathies Market Layout

• 7.1. By Indication
  • 7.1.1. Thalassemia
  • 7.1.2. Sickle Cell Anemia
  • 7.1.3. Others
• 7.2. By Treatment
  • 7.2.1. Stem Cell Therapy
  • 7.2.2. Blood Transfusion
  • 7.2.3. Iron Chelation Therapy
  • 7.2.4. Others
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.1.2. Canada Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.1.3. Mexico Hemoglobinopathies Market in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.2.2. Germany Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.2.4. Italy Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.2.5. Spain Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Hemoglobinopathies Market in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.3.2. Japan Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.3.3. India Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.3.4. Australia Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.3.5. South Korea Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia Pacific Hemoglobinopathies Market in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.4.2. Africa Hemoglobinopathies Market in USD million (2021-2030)
    • 7.3.4.3. South America Hemoglobinopathies Market in USD million (2021-2030)

8. Hemoglobinopathies Market Company and Product Profiles

• 8.1. Global Blood Therapeutics, Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Sanofi
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. bluebird bio, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Bristol-Myers Squibb Company
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Emmaus Medical, Inc,
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Novartis
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Merck KGaA,
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Chiesi USA, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. ApoPharma Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Alvogen.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us